Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Adagene Inc ADR (ADAG)

Adagene Inc ADR (ADAG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates GlobeNewswire - Wed Aug 12, 6:30AM CDT

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has...

ADAG : 3.64 (+3.70%)
MarketBeat.com
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer MarketBeat - Tue May 19, 4:07PM CDT

Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen...

ADAG : 3.64 (+3.70%)
Adagene to Participate in Two Upcoming Investor Conferences GlobeNewswire - Tue May 12, 7:30AM CDT

SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming...

ADAG : 3.64 (+3.70%)
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types GlobeNewswire - Fri Apr 17, 3:01PM CDT

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab +...

ADAG : 3.64 (+3.70%)
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board GlobeNewswire - Tue Apr 14, 6:00AM CDT

SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...

ADAG : 3.64 (+3.70%)
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs GlobeNewswire - Thu Apr 2, 6:10AM CDT

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed...

ADAG : 3.64 (+3.70%)
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) GlobeNewswire - Thu Apr 2, 6:01AM CDT

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and...

ADAG : 3.64 (+3.70%)
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response GlobeNewswire - Thu Apr 2, 6:00AM CDT

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg...

ADAG : 3.64 (+3.70%)
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Apr 1, 4:00PM CDT

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival...

ADAG : 3.64 (+3.70%)
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA GlobeNewswire - Tue Mar 17, 3:35PM CDT

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the...

ADAG : 3.64 (+3.70%)

Barchart Exclusives

3 Top Dividend Stocks to Buy in September Barchart - Tue Sep 1, 6:30PM CDT
Chevron, Realty Income, and NextEra bring more than just yield to the table. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.